These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group. Retina; 2008 Apr; 28(10):1387-94. PubMed ID: 18827735 [Abstract] [Full Text] [Related]
3. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Retina; 2007 Apr; 27(4):432-8. PubMed ID: 17420694 [Abstract] [Full Text] [Related]
4. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group. Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [Abstract] [Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C. J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [Abstract] [Full Text] [Related]
14. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration. Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C. Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335 [Abstract] [Full Text] [Related]
15. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Costagliola C, Romano M, Corte MD, Perrotta R, Menzione M, Rinaldi M, Semeraro F, Parmeggiani F. Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817 [Abstract] [Full Text] [Related]
16. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T, Hoeh AE, Ruppenstein M, Kretz FT, Dithmar S. Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [Abstract] [Full Text] [Related]
17. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K, Sonmez PA, Ozkan SS, Atmaca LS. Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [Abstract] [Full Text] [Related]
18. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Retina; 2006 Apr; 26(9):994-8. PubMed ID: 17151485 [Abstract] [Full Text] [Related]
19. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Melamud A, Stinnett S, Fekrat S. Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144 [Abstract] [Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM, Lai TY, Liu DT, Lam DS. Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [Abstract] [Full Text] [Related] Page: [Next] [New Search]